본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke: A Retrospective Analysis ...
  • 작성일2020-02-07
  • 최종수정일2020-02-07
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 808

Stroke, 2019. 50, 1184-1192, DOI: https://doi.org/10.1161/STROKEAHA.119.024786


Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke: A Retrospective Analysis of the Nationwide Multicenter Stroke Registry

Dohoung Kim, Jong-Moo Park;Kyusik Kang;Yong-Jin Cho;Keun-Sik Hong;Kyung Bok Lee;Tai Hwan Park;Soo Joo Lee;Jae Guk Kim;Moon-Ku Han;Beom Joon Kim;Jun Lee;Jae-Kwan Cha;Dae-Hyun Kim;Hyun-Wook Nah;Dong-Eog Kim;Wi-Sun Ryu;Joon-Tae Kim;Kang-Ho Choi;Jay Chol Choi;Byung-Chul Lee;Kyung-Ho Yu;Mi Sun Oh;Wook-Joo Kim;Jee-Hyun Kwon;Dong-Ick Shin;Sung-Il Sohn;Jeong-Ho Hong;Ji Sung Lee;Juneyoung Lee;Philip B. Gorelick;MPH; Hee-Joon Bae;on behalf of Clinical Research Collaboration for Stroke in Korea (CRCS-K) Investigators


Abstract

    Background and Purpose

    Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dualantiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events. There is apaucity of data, however, on the efficacy or effectiveness of such an approach in the treatment of stroke patients withsymptomatic large artery atherosclerotic occlusive disease.

    Methods

    We used a multicenter stroke registry database (Clinical Research Collaboration for Stroke in Korea) to analyzeacute ischemic stroke patients due to large artery atherosclerotic occlusive disease who were treated with aspirin alone orcombination of clopidogrel and aspirin from May 2008 to May 2015. The results were analyzed by intention-to-treat, perprotocol,and as-treated methodologies. The primary end point was the 1-year composite outcome of stroke recurrence,myocardial infarction, and all-cause death. To balance the differences between groups, a frailty model using propensityscores and inverse probability of treatment weighting was used.

    Results

    A total of 5934 patients with symptomatic large artery atherosclerotic occlusive disease were treated either with clopidogrel plus aspirin (n=2903, 49%) or aspirin (n=3031, 51%). The frequency of the primary outcome was 12%(n=353) in the clopidogrel-aspirin group and 14% (n=410) in the aspirin group. The hazards of the primary outcome withcombination over aspirin only were significantly reduced in the per-protocol and as-treated analyses (hazard ratio, 0.71;95% CI, 0.57–0.88; P=0.002 and hazard ratio, 0.81; 95% CI, 0.69–0.96; P=0.02, respectively), but there was borderlinesignificance in the intention-to-treat analysis (hazard ratio, 0.86; 95% CI, 0.74–1.01; P=0.06). Combination therapy wasbeneficial for all-cause death in all analyses but did not reduce recurrent stroke.

    Conclusions

    Compared with patients receiving aspirin monotherapy, the primary outcome seemed to occur less frequently in patients receiving dual antiplatelet therapy, which is explained mainly by the decrease of all-cause death. Since this is a nonrandomized, retrospective, observational study, our study should be cautiously interpreted.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시" 조건에 따라 이용할 수 있습니다.
TOP